Hemostasis Learning Essentials - Series 5 Assessment

Continue Continue Continue Continue Continue Continue Continue Continue Continue Continue Continue Continue Continue Continue Continue Continue Continue Continue Continue Continue Continue Continue Continue Continue Continue Continue Continue Continue Continue Continue Continue Continue Continue Continue Continue Continue Continue Continue Continue Continue Continue Continue Continue Continue Continue Untitled Scene Master Template HOOD05162003052540 | Effective Date: 26-Nov-2019 Hemostasis Learning Essentials Series 5 – Anti-Phospholipid Syndrome and Other Acquired Coagulopathies This assessment covers the content in the Series 5 topic. Welcome ? Objectives-Series 5 Webinars It is recommended that the webinars in the Hemostasis Learning Essentials Series 5- Anti-Phospholipid Syndrome and Other Acquired Coagulopathies are completed prior to taking this assessment. Select each webinar title to review the learning objectives. Lupus Anticoagulant: Laboratory Investigation and Methods Webinar Lupus Anticoagulant: Tests for Antiphospholipid Syndrome Webinar Lupus Anticoagulant: Clinical Aspects of Antiphospholipid Syndrome Webinar Disseminated Intravascular Coagulation (DIC) Webinar COVID and VITT Webinar ? Objectives COVID and VITT Webinar At the end of this session you will be able to: Explain the pathophysiology of COVID-19 in relation to thrombosis, including bronchoalveolar hemostasis, pulmonary thrombosis, and viral endotheliaopathy Describe how COVID-19 related thrombosis is diagnosed and treated Explain what D-dimers and platelet counts tell us about the pathophysiology of COVID-19 Explain the relationship between the COVID-19 vaccine and VITT Describe the features and management of VITT of DIC Disseminated Intravascular Coagulation (DIC) Webinar At the end of this session you will be able to: Explain the process of normal coagulation Describe the role of thrombin in physiological hemostasis Describe the impact of the unregulated generation of thrombin due to DIC Explain how DIC can cause bleeding, thrombosis, or both simultaneously in the patient Explain how DIC is diagnosed List the steps involved in management of DIC Lupus Anticoagulant: Clinical Aspects of Antiphospholipid Syndrome Webinar At the end of this session you will be able to: Identify the two main conditions caused by APS Describe the clinical criteria for thrombosis and pregnancy morbidity Describe the laboratory criteria for APS diagnosis Describe the extra-criteria manifestations of APS Explain how antiphospholipid antibodies cause clinical problems Explain when testing for APS is appropriate Explain how APS is treated Lupus Anticoagulant: Tests for Antiphospholipid Syndrome Webinar At the end of this session you will be able to: Explain the role of platelets in coagulation Describe coagulation tests and how they are performed Describe how basic tests employing lupus anticoagulant are performed and their supporting principles Describe the specific aspects of lupus anticoagulant tests, including preparation, timing of the tests, and testing of patients on anticoagulants Lupus Anticoagulant: Laboratory Investigation and Methods Webinar At the end of this session you will be able to: Define the laboratory criteria for the diagnosis of antiphospholipid antibody syndrome (APLS) Distinguish between a factor inhibitor and a lupus inhibitor Describe the most commonly used tests for the laboratory diagnosis of APLS Describe some of the pitfalls of APLS testing Disclaimer Please note that the learning material is for training purposes only. For the proper use of the software or hardware, please always use the Operator Manual or Instructions for Use (hereinafter collectively “Operator Manual”) issued by Siemens Healthineers. This material is to be used as training material only and shall by no means substitute the Operator Manual. Any material used in this training will not be updated on a regular basis and does not necessarily reflect the latest version of the software and hardware available at the time of the training. The Operator Manual shall be used as your main reference, in particular for relevant safety information like warnings and cautions. Please note: Some functions shown in this material are optional and might not be part of your system. Certain products, product related claims or functionalities (hereinafter collectively “Functionality”) may not (yet) be commercially available in your country. Due to regulatory requirements, the future availability of said Functionalities in any specific country is not guaranteed. Please contact your local Siemens Healthineers sales representative for the most current information. The reproduction, transmission or distribution of this training or its contents is not permitted without express written authority. Offenders will be liable for damages. All names and data of patients, parameters and configuration dependent designations are fictional and examples only. All rights, including rights created by patent grant or registration of a utility model or design, are reserved. Unrestricted | Published by Siemens Healthineers AG | © Siemens Healthineers AG, 2024 Siemens Healthineers HQ | Siemens Healthineers AG Siemensstr. 3 91301 Forchheim Germany Phone: +49 9191 18-0 siemens-healthineers.com ? Disclaimer Assessment Start ? This assessment will test your retention of the presented content. A passing score of 80% or higher is required to complete the course and earn your certificate . Assessment questions must be answered completely to receive full credit. Partial credit will not be given for assessment questions that require multiple answers. You may repeat the assessment as many times as needed. Assessment Select the best answer. ? Non-Parallelism in results when using Multi-Dilution-Assay MDA Question 1 of 13 How does the presence of a lupus inhibitor affect factor assay results? Parallelism in results Parallelism in results when using Multi-Dilution-Assay MDA Multiple Choice ? Select three (3) answers. Question 2 of 13 When testing for Lupus Anticoagulant Syndrome, which of the following helps to avoid false positive results? Apply the three step procedure: screen, mix, and confirm Calculate cutoff value by 99th percentile Test in the acute phase (elevated FVIII along with an increase in vWF) Repeat testing after 12 weeks Multiple Answer One or more answers are incorrect. ? Select four (4) answers. Question 3 of 13 Thaw frozen plasma at 37 degrees for 5 minutes in water bath before testing Thaw frozen plasma at 37 degrees for 5 minutes in water bath before testing Thaw frozen plasma at 37 degrees for 5 minutes in water bath before testing Which of the following sample preparation guidelines are important for Lupus Anticoagulant testing? Double centrifugation at 2000g for 15 minutes at room temperature to remove platelets from plasma Freeze plasma within 4 hours of collection if LA testing is postponed Avoid multiple freeze/thawing cycles Thaw frozen plasma at 37 degrees C for 5 minutes in water bath and mix before testing Multiple Answer One or more answers are incorrect. ? Select three (3) answers. Question 4 of 13 Why should Lupus Anticoagulant Testing be avoided soon after a thrombotic event? Raised levels of FVIII shorten the APTT or C-reactive protein interfering with phospholipids in the reagent May result in false positives Results interpretation is problematic due to baseline prolongation of PT/APTT May result in false negatives Multiple Answer One or more answers are incorrect. ? Select four (4) answers. Question 5 of 13 Older patients (over 50 years) with unprovoked VTE, ischemic stroke or TIA Older patients (over 50 years) with unprovoked VTE, ischemic stroke or TIA Older patients (over 50 years) with unprovoked VTE, ischemic stroke or TIA What types of patients should be tested for Lupus Anticoagulant? Younger patients (under 50 years) with unprovoked VTE, ischemic stroke or TIA Patients with VTE at unusual sites Patients who experienced pregnancy morbidity Younger patients (under 50 years) with arterial thrombosis in other sites Multiple Answer One or more answers are incorrect. Select the best answer. ? Warfarin therapy Antiplatelet agents Question 6 of 13 What is the most common treatment for patients with APS who have experienced a thrombotic event? Vitamin D therapy Hydroxychloroquine Multiple Choice ? Select three (3) answers. Question 7 of 13 Which of the following is true of Disseminated Intravascular Coagulation (DIC)? Characterized by intravascular activation of coagulation with loss of localization Can originate from and cause damage to the microvasculature Can cause high levels of factor VIII and platelets in pregnant patients Can produce organ dysfunction if severe Multiple Answer One or more answers are incorrect. ? Select five (5) answers. Question 8 of 13 Decreases platelets Increases platelets Increases platelets Increases platelets What are the outcomes of unregulated thrombin in DIC? Increases coagulation Decreases anticoagulant Decreases antifibrinolysis Increases fibrinolysis Multiple Answer One or more answers are incorrect. Cancer patient with late trauma-Procoagulant DIC Predominantly Thrombosis Cancer patient-Subclinical DIC Laboratory abnormalities only Obstetrical DIC with early trauma-Hyperfibrinolytic DIC Predominantly Bleeding Drag each response from the right column to its corresponding item in the left column. How does each category of DIC affect patients? ? Question 9 of 13 Matching One or more answers are incorrect. ? Select four (4) answers. Question 10 of 13 Decreased fibrin related marker (D-dimer) Decreased fibrin related marker (D-dimer) Decreased fibrin related marker (D-dimer) For patients with conditions that can trigger DIC, which of the following are evaluated in the laboratory diagnosis of DIC? Low platelet count (<100x109/L) Prolonged PT and APTT Elevated fibrin related marker (D-dimer) Low fibrinogen (<1 or 1.5 g/L) Multiple Answer One or more answers are incorrect. ? Select four (4) answers. Question 11 of 13 Warfarin therapy Warfarin therapy Warfarin therapy Which of the following are some of the steps in managing DIC? Management of the underlying condition Inhibition of excess thrombin Supportive care with blood products Modulating hyperfibrinolytic response Multiple Answer One or more answers are incorrect. Select the best answer. ? Pulmonary thrombosis Deep vein thrombosis (DVT) Question 12 of 13 What is the most common thrombotic manifestation in COVID-19? Pulmonary embolism Myocardial Infarction Multiple Choice ? Select four (4) answers. Question 13 of 13 APTT Which of the following diagnostic tests are used to detect thrombosis with COVID-19? D-dimer Prothrombin time Fibrinogen Platelet count Multiple Answer One or more answers are incorrect. Assessment Results YOUR SCORE: PASSING SCORE: Review Retry Retry Continue Continue Continue %Quiz2.ScorePercent%% %Quiz2.PassPercent%% ? Assessment Results You did not pass the course. Take time to review the assessment then select Retry to continue. Congratulations. You passed the course.. Exit To access your Certificate of Completion, select the Certificates tab from the learning activity overview page. You can also access the certificate from your PEPconnect transcript. ? You have completed the Hemostasis Learning Essentials Series 5 - Anti-Phospholipid Syndrome and Other Acquired Coagulopathies Assessment. Completion details, certificates tab Navigation Select the icon above to open the table of contents. Click Next to continue. Next Welcome Slide The timeline displays the slide progression. Slide the orange bar backwards to rewind the timeline. Click Next to continue. Next Tmeline Select the CC icon to display closed captioning (subtitles). Click Next to continue. Next Caption Icon Select the buttons to learn more about a topic. Be sure to review all topics before navigating to the next slide. Click Next to continue. Next Tab Arrow Slide Select the X to close the pop-up. Click Next to continue. Next Layer Slide Some images may have a magnifier icon. Select the image to see an enlarged view. Select it again to return to the normal view. Click Next to continue. Next Zoom Slide Some images have a magnifier icon in the bottom-left corner. Select these image to see an enlarged view of the image. Select the image again to return to the normal view. Videos should default to the optimal resolution. However, to change the video resolution select the gear icon. Click Next to continue. Next Video Slide Some images have a magnifier icon in the bottom-left corner. Select these image to see an enlarged view of the image. Select the image again to return to the normal view. Select Submit to record your response. Click the X in the upper right corner to exit the navigation help. Assessment Slide QR700008981| Effective Date: 29 May 2024 1.1 Welcome 1.2 Objectives 1.3 Disclaimer 1.4 Assessment